Formulary Search

NHSE specialised commissioned services only. Not commissioned from any acute Trust in Surrey Heartlands.

However, this drug may be used in the emergency treatment of urea cycle disorders in patients on acute admission.

NHSE Specialist Centres - only commissioned from RSFT in Surrey Heartlands.
SASH - only for use under shared care arrangements with specialist centres.

Lecanemab used in Alzheimer’s disease is currently not available in the NHS. Eisai (the manufacturer and market authorisation holder for lecanemab (Leqembi®)) has started to make the drug available for patients to access through independent sector clinics.
 

The information from NHSE here provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).

Refer to St Luke's Protocols for current indications and further detail.
Filgrastim is the preferred treatment option.

1st month supply from specialist team before request for primary care prescribing.

Off-label use

Primary Care prescribing appropriate on recommendation from the specialist team.

EXISTING patients only. Do not initiate in new patients.

On advice from palliative care specialist team

NHSE specialised commissioned services only. Not commissioned from any acute Trust in Surrey Heartlands.
L-carnitine / levocarnitine in valproate toxicity has a separate formulary entry.

NHSE specialised commissioned services only. Not commissioned from any acute Trust in Surrey Heartlands.

However, this drug may be used in the emergency treatment of urea cycle disorders in patients on acute admission

NHSE specialised commissioned services only. Not commissioned from any acute Trust in Surrey Heartlands.

However, this drug may be used in the emergency treatment of urea cycle disorders in patients on acute admission

30% paediatric solution (1.5 gram in 5ml)

This product has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an applicationto the APC.

Nebuliser solution

This drug (for this indication) has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.

This drug (for this indication) has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.

This drug (for this indication) has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an application to APC.

Levosert

Mirena

May be particularly useful in women with heavy menstrual bleeding requiring (reversible) contraception.

Option for polycystic ovary syndrome.

RSFT: 2nd line for contraception and heavy menstrual bleeding for use when Benilexa is unsuitable of unavailable.

RSFT: Endometrial protection as part of HRT in both peri and postmenopausal women

Norgeston

progesterone only pill, POP

Jaydess 13.5mg

SASH: Jaydess is restriced to those patients who require a smaller size / lower dose of levonorgestrel

Kyleena 19.5mg.

RSFT: Kyleena should only be used in nulliparous patients under 25 years onld and those unable to use the alternative devices.

Benilexa One Handed

RSFT: 1st line for contraception and treatment of heavy menstrual bleeding for females between the ages of 18 and 45 years.

Option for polycystic ovary syndrome. May be particularly useful in women wih hevy menstrual bleeding requiring (reversible) contraception.

Levonorgestrel recommended for replacement every 5 years (off-label use) as per BMS: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf

• Mirena - licensed for endometrial protection but only for a duration of 4 years. Agreed to use for a duration of 5 years before replacement (off-label).